MorphoSys AG buy Ellritze
Start price
30.08.21
/
70%
€47.81
Target price
30.08.22
€53.00
Performance (%)
5.67%
End price
04.09.21
€50.52
Summary
This prediction ended on 04.09.21 with a price of €50.52. With a performance of 5.67%, the BUY prediction by Ellritze for MorphoSys AG closed with a slight gain. Ellritze has 70% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| MorphoSys AG | 0.000% | 0.000% | 256.861% |
| iShares Core DAX® | 1.051% | -1.833% | 12.822% |
| iShares Nasdaq 100 | -0.547% | -3.738% | 40.625% |
| iShares Nikkei 225® | -1.778% | -8.115% | 16.092% |
| iShares S&P 500 | 0.002% | -2.226% | 28.387% |
According to Ellritze what are the pros and cons of MorphoSys AG for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Innovative
Top 10 in its market
Future proof or reliable business model
Cons
Higher risks for its business
Significant cyclical dependencies